|
1
|
Merckel LG, Knuttel FM, Deckers R, van
Dalen T, Schubert G, Peters NH, Weits T, van Diest PJ, Mali WP,
Vaessen PH, et al: First clinical experience with a dedicated
MRI-guided high-intensity focused ultrasound system for breast
cancer ablation. Eur Radiol. 26:4037–4046. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Onitilo AA, Engel JM, Greenlee RT and
Mukesh BN: Breast cancer subtypes based on ER/PR and Her2
expression: Comparison of clinicopathologic features and survival.
Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong
C, Su F and Song E: Pretreatment neutrophil-to-lymphocyte ratio is
correlated with response to neoadjuvant chemotherapy as an
independent prognostic indicator in breast cancer patients: A
retrospective study. BMC Cancer. 16:3202016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee
SH, Chie EK, Han W, Kim DW, Moon WK, et al: Prognostic impact of
clinicopathologic parameters in stage II/III breast cancer treated
with neoadjuvant docetaxel and doxorubicin chemotherapy:
Paradoxical features of the triple negative breast cancer. BMC
Cancer. 7:2032007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siroy A, Abdul-Karim FW, Miedler J, Fong
N, Fu P, Gilmore H and Baar J: MUC1 is expressed at high frequency
in early-stage basal-like triple-negative breast cancer. Hum
Pathol. 44:2159–2166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abe H, Schacht D, Kulkarni K, Shimauchi A,
Yamaguchi K, Sennett CA and Jiang Y: Accuracy of axillary lymph
node staging in breast cancer patients: An observer-performance
study comparison of MRI and ultrasound. Acad Radiol. 20:1399–1404.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuhl C, Kuhn W, Braun M and Schild H:
Pre-operative staging of breast cancer with breast MRI: One step
forward, two steps back? Breast. 16 (Suppl 2):S34–S44. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fouad TM, Barrera AMG, Reuben JM, Lucci A,
Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, et
al: Inflammatory breast cancer: A proposed conceptual shift in the
UICC-AJCC TNM staging system. Lancet Oncol. 18:e228–e232. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gahlaut R, Bennett A, Fatayer H, Dall BJ,
Sharma N, Velikova G, Perren T, Dodwell D, Lansdown M and Shaaban
AM: Effect of neoadjuvant chemotherapy on breast cancer phenotype,
ER/PR and HER2 expression - Implications for the practising
oncologist. Eur J Cancer. 60:40–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li
HY, Ren GS, Wu KN, Wang DL and Kong LQ: Discordance and clinical
significance of ER, PR, and HER2 status between primary breast
cancer and synchronous axillary lymph node metastasis. Med Oncol.
31:7982014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nik-Zainal S, Davies H, Staaf J,
Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB,
Martin S, Wedge DC, et al: Landscape of somatic mutations in 560
breast cancer whole-genome sequences. Nature. 534:47–54. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng J, Kyrillos A, Liederbach E, Spear
GG, Ecanow J, Wang CH, Czechura T, Kantor O, Miller M, Winchester
DJ, et al: Clinical accuracy of preoperative breast MRI for breast
cancer. J Surg Oncol. 115:924–931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Jia M, Qin X, Hu J, Zhang X and Zhou
G: Harmful effect of ERβ on BCRP-mediated drug resistance and cell
proliferation in ERα/PR-negative breast cancer. FEBS J.
280:6128–6140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Segara D, Krop IE, Garber JE, Winer E,
Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD,
et al: Does MRI predict pathologic tumor response in women with
breast cancer undergoing preoperative chemotherapy? J Surg Oncol.
96:474–480. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heijnsdijk EA, Warner E, Gilbert FJ,
Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma
G, Ramsay EA, et al: Differences in natural history between breast
cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI
screening-MRISC, MARIBS, and Canadian studies combined. Cancer
Epidemiol Biomarkers Prev. 21:1458–1468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
DeLeo MJ III, Domchek SM, Kontos D, Conant
E, Chen J and Weinstein S: Breast MRI fibroglandular volume and
parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before
and immediately after risk-reducing salpingo-oophorectomy. AJR Am J
Roentgenol. 204:669–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rudat V, Nour A, Almuraikhi N, Ghoniemy I,
Brune-Erber I, Almasri N and El-Maghraby T: MRI and ultrasonography
for assessing multifocal disease and tumor size in breast cancer:
Comparison with histopathological results. Gulf J Oncol. 1:65–72.
2015.
|
|
19
|
Partridge SC, Nissan N, Rahbar H, Kitsch
AE and Sigmund EE: Diffusion-weighted breast MRI: Clinical
applications and emerging techniques. J Magn Reson Imaging.
45:337–355. 2017. View Article : Google Scholar : PubMed/NCBI
|
